Healthy Volunteers Clinical Trial
— HIFCT-VOfficial title:
Effects of Two Virtual High-intensity Functional Circuit Training Programs on Intra-abdominal Fat, Body Composition, Health-related Quality of Life, and Some Components of Physical Fitness in Adults With Abdominal Obesity
It is estimated that by 2030 one in five women and one in seven men will be obese, equivalent to more than 1 billion people around the world. It should be noted that the largest number of people with obesity live in countries with low and moderate-income. In 2019, more than 160 million years of healthy life were lost in the world, due to a high body mass index (BMI), this represents more than 20% of all years of healthy life lost due to chronic diseases. Therefore, it is essential to stop the increase in obesity and reduce it at all ages, which demands comprehensive actions at the global level. Scientific evidence suggests that people with a normal BMI, but with abdominal obesity, have a higher mortality risk compared to those with a similar or even higher BMI. In addition, visceral adiposity has been associated with worse survival and with colorectal cancer. Several methods of physical exercise have been used to counteract the adverse effects of obesity, including high-intensity functional circuit training (HIFCT). Scientific evidence indicates that HIFCT reduces fat mass, body mass, BMI, and waist circumference and improves muscle strength, maximal oxygen uptake, and health-related quality of life in overweight, obese, inactive, and with other diseases. However, no research assessed intra-abdominal fat (IAF), which, more than subcutaneous fat, is associated with cardiovascular risk factors. In addition, these studies had important methodological limitations. Therefore, the primary purpose of this study is to identify the effect of two HIFCT protocols, prolonged load (HIFCT-P) and short load (HIFCT-S), performed in a virtual environment for ten weeks on intra-abdominal fat in people between 18-40 years-old with abdominal obesity.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | November 30, 2023 |
Est. primary completion date | November 15, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Healthy women and men. - Physical activity (<600 to =1500 MET/min/wk). - Waist circumference (=87cm). Exclusion Criteria: - Have performed high intensity exercises or HIFCT in the last two months. - Smoking. - History of cardiovascular disease. - History of coronary heart disease. - Pregnancy. - Breast-feeding women. - Psychological, neuromotor, and/or osteo-muscular conditions that may affect participation in an exercise program. |
Country | Name | City | State |
---|---|---|---|
Colombia | Centro de Formación en Actividad Física y Cultura-SENA Distrito Capital | Bogotá | Cundinamarca |
Lead Sponsor | Collaborator |
---|---|
Universidad de Antioquia |
Colombia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Fat mass, fat-free mass, whole-body and segmental skeletal muscle mass. | Body Composition Analyzer Seca mBCA 515. Individuals will be instructed to wear light clothing, and stand barefoot on the device, following manufacturer protocols. All assessments will take place at the same time of day. | Baseline and 10-weeks | |
Primary | Change in intra-abdominal fat | Body Composition Analyzer Seca mBCA 515. The measurement results allow estimating intra-abdominal fat in liters. Values <27 L are considered normal, >27 L to <43 L are considered elevated, and =43 L are considered high. Individuals will be instructed to wear light clothing, and stand barefoot on the device, following manufacturer protocols.All assessments will take place at the same time of day. | Baseline and 10-weeks | |
Secondary | Change in waist circumference | A flexible tape measure: Waist circumference will be measured following standard procedures, at the mid-point between the lower costal edge and the iliac crest. (Klein et al., 2007 https://doi.org/10.1093/ajcn/85.5.1197) | Baseline and 10-weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT06236009 -
A First-In-Human Study of TAK-004 in Healthy Adults
|
Phase 1 |